InVivo Therapeutics In The News
InVivo Therapeutics gains IDE for biopolymer product study
April 8, 2013
Medical Device Daily – InVivo Therapeutics Holdings (Cambridge, Massachusetts), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, reported FDA has approved the company’s Investigational Device Exemption (IDE) to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.
InVivo Therapeutics gets approval for human trials
April 05, 2013
BloombergBusinessweek – InVivo Therapeutics Holdings Corp. said Friday that the Food and Drug Administration will allow it to start human trials of an experimental product that is intended to treat spinal cord injuries.
Progress for Pervasis and InVivo: A Boost for Regenerative Efforts? .
April 19, 2012
Xconomy – Last week brought good news for two Cambridge, MA companies pursuing different methods for repairing damaged body parts. Pervasis Therapeutics, which developed a cell-based method for fixing blood vessels, was acquired by Irish drug giant Shire (NASDAQ: SHPGY) on April 12. The next day, Cambridge-based InVivo Therapeutics (OTCBB: NVIV) said it expected it would soon win clearance from the FDA to begin human trials of the spinal cord injury treatment it has been working on for years.
Top picks 2012: InVivo Therapeutics.
January 9, 2012
MSN Money – The financial impact of spinal cord injury (SCI) is staggering, estimated at between $244,000 and $829,000 in the first year alone. Over a lifetime the costs could add up to $1 to $4 million. The annual global market for SCI is estimated at $10 billion. There are currently no successful treatment options for SCI patients. InVivo Therapeutics (NVIV +3.37%) utilizes biodegradable polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. In 2005 Frank Reynolds and Robert Langer, ScD., professor at MIT and finalist for the Noble Prize in Medicine this year, founded InVivo on the basis of proprietary technology co-invented by Dr. Langer and Joseph P. Vacanti, M.D. with Massachusetts General Hospital.
BI Research Report on InVivo Therapeutics Corp.
December 21, 2011
BI Research – This fall, Geron’s Medical Director of Regenerative Medicine quietly left the company for the position of Chief Science Officer with much smaller, much less well known, InVivo. Geron was the anointed leader in embryonic stem cell research with the world’s first Phase I stem cell clinical trial on humans underway testing for efficacy on spinal cord injury. However a month or two later Geron announced that it was exiting stem cells to focus on its cancer program where it had 6 Phase II trials. Given that I needed to put out an update on this I started reading and clicking on links and I came across the tidbit that lesser-known InVivo was seeing a benefit from Geron’s announcement with investor interest shifting to it. It too was involved with spinal cord injury research, (apparently catnip for investors), but in contrast to Geron, this is currently InVivo’s main focus… and what I learned blew me away.
InVivo signs lease for One Kendall
December 1, 2011
BOSTON BUSINESS JOURNAL – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a life sciences company focused on potential treatments for spinal cord injuries has entered into a six-year lease for a new 21,000 square-foot headquarters at One Kendall Square in Cambridge, Mass.
Geron’s (NASDAQ:GERN) News Shocker Sets InVivo (OTC:NVIV) Up For Prime Time
October 15, 2011
MARKET PLAYGROUND -A monumental decision by Geron Corporation (NASDAQ:GERN) has drastically altered the landscape of embryonic stem cell research and sent shares to below the two dollar mark in a hurry, but it also has heavy implications on the race to bring an effective treatment for spinal cord injuries (SCI) to market.
A New Hope for Treating Spinal Cord Injury: 5 Points on InVivo Therapeutics’ Technology
October 11, 2011
by LAURA MILLER – InVivo Therapeutics, based in Cambridge, Mass., was founded to focus on research and development of treatment for patients with spinal cord injuries (SCI). Currently, there are no effective treatments for these patients, and much of the research focuses on treating the symptoms of SCI instead of the underlying pathology…
InViivo Therapeutics feature article – “Monkeys Walk with Spinal Implant, Humans Next”
August 15, 2010
by MARIA FONTANAZZA – The once-paralyzed CEO of InVivo Therapeutics designed his own physical therapy program and regained the ability to walk. Not all patients with spinal cord injuries (SCIs) are so lucky, and Frank Reynolds wants to save as many of them as possible from life in a wheelchair with an implant that protects the spinal cord from inflammation, further bleeding, and cell death following SCI…
InViivo Therapeutics coverage by “Zacks Research”
July 27, 2010
by JASON NAPODANO, CFA – Zacks Small-Cap Research listed coverage for InVivo Therapeutics (NVIV.OB)
InViivo Therapeutics feature article – “The Gray Sheet”
July 25, 2010
by MARK HOLMER – InVivo Therapeutics says it will file and investigational device exemption for its bio-polymer spinal scaffolding by June 30 and begin a clinical trial by year-end.
Dr. Jonathan Slotkin M.D. named Medical Director – “Medical Device Daily”
July 13, 2010
People In The News Section – InVivo Therapeutics (Cambridge, Massachusetts) has named Jonathan Slotkin, MD, as medical director. In this newly created position, Slotkin will also continue his work as a neurosurgeon at Washington Brain & Spine Institute. InVivo specializes in using polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury.
InVivo submits IDE for spinal injury device – “Medical Device Daily”
July 11, 2010
By AMANDA PEDERSEN Medical Device Daily Senior Staff Writer – Frank Reynolds spent fi ve years in bed wearing a body brace and staring at the ceiling. Not only is the formerly paralyzed man able to walk today, he is leading a company that is developing technologies for spinal cord treatment through a brand new approach. Instead of focusing exclusively on regeneration, InVivo Therapeutics (Cambridge, Massachusetts) concentrates on neuro-protection, Reynolds, CEO of InVivo, told Medical Device Daily.